pazopanib

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Osteosarcoma

Conditions

Osteosarcoma, Metastatic Osteosarcoma

Trial Timeline

Apr 1, 2013 → May 1, 2017

NCT ID

NCT01759303

About pazopanib

pazopanib is a phase 2 stage product being developed by Novartis for Osteosarcoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01759303. Target conditions include Osteosarcoma, Metastatic Osteosarcoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03200717	Phase 2	Completed	Nov 14, 2017	Aug 10, 2021	Advanced Renal Cell Carcinoma
NCT02193152	Phase 2	Terminated	Apr 27, 2015	Dec 24, 2019	Carcinoma, Non-Small Cell Lung
NCT02300545	Phase 2	Completed	Apr 8, 2015	Jul 11, 2020	Sarcoma, Soft Tissue
NCT01956669	Phase 2	Completed	Oct 8, 2014	Nov 5, 2019	Solid Tumours
NCT01832259	Phase 2	Completed	Aug 1, 2013	Aug 9, 2018	Adenocarcinoma of the Prostate
NCT01759303	Phase 2	Terminated	Apr 1, 2013	May 1, 2017	Osteosarcoma
NCT01642017	Phase 1	Terminated	Nov 22, 2012	Mar 1, 2018	Metastatic Cancer (Different Solid Tumour Types)
NCT01649778	Pre-clinical	Completed	Jul 19, 2012	Jul 3, 2017	Carcinoma, Renal Cell
NCT01506596	Phase 2	Completed	Mar 1, 2012	Mar 1, 2016	Liposarcoma
NCT01521715	Approved	Completed	Jan 24, 2012	Jul 31, 2017	Locally Advanced and/or Metastatic Renal Cell Carcinoma
NCT01361334	Phase 2	Completed	Jun 1, 2011	Mar 1, 2016	Acute Myeloid Leukemia
NCT01566747	Phase 2	Completed	Mar 1, 2011	Jul 15, 2020	Renal Cell Carcinoma
NCT00387205	Phase 1	Completed	Jun 20, 2006	Mar 8, 2018	Carcinoma, Renal Cell

Competing Products

18 competing products in Osteosarcoma

See all competitors

Product	Company	Stage	Hype Score
Azenosertib + Gemcitabine	Zentalis Pharmaceuticals	Phase 1/2	33
Lenvatinib + Ifosfamide + Etoposide + Lenvatinib	Eisai	Phase 2	52
Pemetrexed	Eli Lilly	Phase 2	52
pemetrexed	Eli Lilly	Phase 2	52
Camrelizumab in Combination With Neoadjuvant Chemotherapy	Jiangsu Hengrui Medicine	Phase 2	52
Apatinib	Jiangsu Hengrui Medicine	Phase 2	52
Olaparib + Ceralasertib	AstraZeneca	Phase 2	52
Saracatinib + Placebo	AstraZeneca	Phase 2	52
robatumumab	Merck	Phase 2	52
Pembrolizumab	Merck	Phase 2	52
Avelumab	Pfizer	Phase 2	51
Nivolumab + Azacitidine	Bristol Myers Squibb	Phase 1	32
Nivolumab + Ipilimumab	Bristol Myers Squibb	Phase 2	51
Cisplatin liposomal	Insmed	Phase 1/2	38
Cabozantinib	Ipsen	Phase 2	49
Sm-EDTMP	Jazz Pharmaceuticals	Phase 2	49
LNTH2403 Phase 1 dose + Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).	Lantheus Holdings	Phase 1/2	38
REOLYSIN®	Oncolytics Biotech	Phase 2	44

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved